Spondyloarthritis & psoriatic arthritis
Characterization of a Musculoskeletal Syndrome of Enthesitis and Arthritis in Patients With Atopic Dermatitis Treated With Dupilumab, an Interleukin‐4/13 Inhibitor
Authors' conclusion
We report a new musculoskeletal syndrome of inflammatory enthesitis/arthritis/tenosynovitis in some patients receiving the IL-4 receptor antagonist dupilumab.
Study context
- Population
- Patients with atopic dermatitis (AD) treated with dupilumab who developed new-onset musculoskeletal symptoms, October 2018–February 202136 referred
- Participants
- 470 patients
- Outcome
- Musculoskeletal syndrome of inflammatory enthesitis, arthritis and/or tenosynovitis
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Patients identified with the syndrome (of 36 referred for rheumatologic assessment)
- 26
- Male / female
- 14 / 12
- Mild symptoms
- 16
- Moderate symptoms
- 6
- Severe symptoms
- 4
Observational data: associations, not effects.
Further findings
Management outcomes
- NSAIDs or COX-2 inhibitors, dupilumab dose/frequency reduction and cessation led to improvement, but moderate or severe symptoms persisted for many months
- All patients had very good response of AD to dupilumab
Original publication
Characterization of a Musculoskeletal Syndrome of Enthesitis and Arthritis in Patients With Atopic Dermatitis Treated With Dupilumab, an Interleukin‐4/13 Inhibitor. Arthritis Rheumatol. Published 27 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →